219649-07-7
219649-07-7 structure
- Name: Labetuzumab
- Chemical Name: Labetuzumab
- CAS Number: 219649-07-7
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Cancer
- Create Date: 2022-11-13 14:30:42
- Modify Date: 2025-08-24 23:50:30
-
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy[1].
| Name | Labetuzumab |
|---|
| Description | Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy[1]. |
|---|---|
| Related Catalog | |
| Target |
CEA[1]. |
| In Vivo | Labetuzumab (0.5 mg/rat; i.v.; single) inhibits tumor growth in vivo[1]. Animal Model: Female nu/nu mice (6 to 8-week-old; inject TT cells)[1]. Dosage: 0.5 mg/rat Administration: Intravenous injection; single (1 day post-tumor cell injection) Result: Significantly delaied growth of tumor, and led to 64%-70% inhibition of tumor size between days 32 and 60. |
| References |
| No Any Chemical & Physical Properties |